Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.

Autor: Feld J; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Tremblay D; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Navada SC; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Silverman LR; Division of Hematology/Oncology, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Publikováno v: Leukemia & lymphoma [Leuk Lymphoma] 2023 Mar; Vol. 64 (3), pp. 525-539. Date of Electronic Publication: 2022 Nov 12.

Safety and Efficacy: Clinical Experience of Venetoclax in Combination With Hypomethylating Agents in Both Newly Diagnosed and Relapsed/Refractory Advanced Myeloid Malignancies.

Autor: Feld J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Tremblay D; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Dougherty M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Czaplinska T; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Sanchez G; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Brady C; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Kremyanskaya M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Bar-Natan M; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Keyzner A; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Marcellino BK; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Gabrilove J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Navada SC; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Silverman LR; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., El Jamal SM; Department of Pathology, Molecular and Cell-Based Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Mascarenhas J; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA., Shih AH; Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.

Publikováno v: HemaSphere [Hemasphere] 2021 Mar 09; Vol. 5 (4), pp. e549. Date of Electronic Publication: 2021 Mar 09 (Print Publication: 2021).

Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts.

Autor: Zeidan AM; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA. Electronic address: amer.zeidan@yale.edu., Boddu PC; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Patnaik MM; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Bewersdorf JP; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Stahl M; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Rampal RK; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Shallis R; Section of Hematology, Yale School of Medicine, Yale University, New Haven, CT, USA; Yale Comprehensive Cancer Center, Yale School of Medicine, Yale University, New Haven, CT, USA., Steensma DP; Department of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA., Savona MR; Department of Hematology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA., Sekeres MA; Leukemia Program, Department of Hematology and Medical Oncology, Cleveland Clinic, Cleveland, OH, USA., Roboz GJ; Department of Hematology and Oncology, Weill Cornell Medicine, New York-Presbyterian Hospital, New York, NY, USA., DeAngelo DJ; Department of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA., Schuh AC; Division of Medical Oncology and Hematology, University of Toronto, Toronto, ON, Canada., Padron E; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA., Zeidner JF; Division of Hematology and Oncology, Lineberger Comprehensive Care Center, University of North Carolina, Chapel Hill, NC, USA., Walter RB; Division of Hematology, Fred Hutchinson Cancer Research Center, Seattle, WA, USA., Onida F; Department of Hematology, IRCCS Ca' Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy., Fathi A; Department of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA., DeZern A; Department of Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA., Hobbs G; Department of Hematology, Centre for Leukemia, Massachusetts General Hospital, Boston, MA, USA., Stein EM; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Vyas P; MRC Molecular Haematology Unit, BRC Oxford Department of Haematology, University of Oxford, Oxford, UK., Wei AH; Department of Clinical Haematology, Alfred Hospital, Melbourne, VIC, Australia., Bowen DT; Department of Haematology, Leeds Teaching Hospitals National Health Service Trust, Leeds, UK., Montesinos P; Department of Haematology, Hospital Universitario y Politecnico La Fe, Valencia, Spain; CIBERONC, Instituto Carlos III, University of Valencia, Madrid, Spain., Griffiths EA; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Verma AK; Department of Oncology, Montefiore Medical Center, Albert Einstein College of Medicine, New York, NY, USA., Keyzner A; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Bar-Natan M; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Navada SC; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Kremyanskaya M; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Goldberg AD; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Al-Kali A; Department of Hematology, Mayo Clinic, Rochester, MN, USA., Heaney ML; Department of Hematology, Herbert Irving Comprehensive Care Centre, Columbia University, New York, NY, USA., Nazha A; Department of Hematology, Cleveland Clinic-Taussig Cancer Institute, Cleveland, OH, USA., Salman H; Department of Internal Medicine, Stony Brook University Cancer Center, Stony Brook, NY, USA., Luger S; Department of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA., Pratz KW; Department of Medicine, Hematology and Oncology Division, University of Pennsylvania, Philadelphia, PA, USA., Konig H; Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology and Oncology, Indiana University, Indianapolis, IN, USA., Komrokji R; Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, USA., Deininger M; Huntsman Cancer Institute, Department of Medicine, Division of Hematology and Hematologic Malignancies, University of Utah, Salt Lake City, UT, USA., Cirici BX; Clinical Haematology Department, Josep Carreras Leukaemia Research Institute, Universitat Autònoma de Barcelona, Barcelona, Spain., Bhatt VR; Fred and Pamela Buffett Cancer Center, Department of Oncology and Hematology, University of Nebraska Medical Center, Omaha, NE, USA., Silverman LR; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Erba HP; Duke Cancer Institute, Department of Medicine, Division of Hematologic Malignancies and Cellular Therapies, Durham, NC, USA., Fenaux P; Department of Hematology, Hôpital St Louis, Assistance Publique-Hôpitaux de Paris, Paris, France; Department of Haematology, Paris University, Paris, France., Platzbecker U; Department of Medicine, Division of Translational Hematology, Leipzig University Hospital, Leipzig, Germany., Santini V; Department of Medicine, University of Florence Medical School, Florence, Italy., Wang ES; Leukemia Service, Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Tallman MS; Department of Hematology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Stone RM; Department of Hematology, Division of Leukemia, Dana-Farber Cancer Institute, Boston, MA, USA., Mascarenhas J; Division of Hematology and Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Publikováno v: The Lancet. Haematology [Lancet Haematol] 2020 Aug; Vol. 7 (8), pp. e601-e612. Date of Electronic Publication: 2020 Jun 18.

Myelodysplastic syndromes: a review of therapeutic progress over the past 10 years.

Autor: Feld J; Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine , New York, USA., Belasen A; Department of Medicine, Icahn School of Medicine , New York, USA., Navada SC; Tisch Cancer Institute, Division of Hematology/Oncology, Icahn School of Medicine , New York, USA.

Publikováno v: Expert review of anticancer therapy [Expert Rev Anticancer Ther] 2020 Jun; Vol. 20 (6), pp. 465-482. Date of Electronic Publication: 2020 Jun 01.

Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes.

Autor: Navada SC; Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Place, Box 1079, New York, NY 10029-6574, USA., Silverman LR; Icahn School of Medicine at Mount Sinai, New York, NY, USA.

Publikováno v: Therapeutic advances in hematology [Ther Adv Hematol] 2017 Jan; Vol. 8 (1), pp. 21-27. Date of Electronic Publication: 2016 Oct 20.